Drug
Ponatinib OD
Ponatinib OD: highest development phase Phase 2, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ponatinib 30mg OD NCT04233346 | Phase 2 | Chronic Myeloid Leukemia |
Latest
No recent events.
Follow Ponatinib OD on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.